Recommended

AstraZeneca boosts production capacity at Texas facility following $445m investment
ESMO 2025: Keytruda immunotherapy shows promise in skin cancer
AstraZeneca research illustrates potential of autonomous UVC disinfection in pharma cleanrooms
Webinar: Radiopharmaceuticals’ time-to-result challenge
Ipsen €1bn ImCheck Therapeutics acquisition deal
Phase III data for next-gen green inhaler push GSK closer to Net Zero targets
Lilly progresses Incyte’s JAK inhibitor in major study
news

Rentschler Biopharma marks construction milestone at new German buffer media facility

0
SHARES

The new biopharmaceutical production facility represents the CDMO’s largest single investment at its headquarters in Lauphei, Germany.

Rendering - Rentschler Biopharma Buffer-Media-Station

Rendering of Rentschler Biopharma Buffer Media Station (Credit: Rentschler Biopharma)

Rentschler Biopharma SE is constructing a new buffer media station at its headquarters in Laupheim, Germany, the contract development and manufacturing organisation (CDMO)’s largest single investment at the site thus far.

 

ACCESS your FREE COPY

 


This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.

Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.

What you’ll discover:

  • Key trends shaping the pharmaceutical formulation sector
  • Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
  • Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
  • And more!

Don’t miss your chance to access this exclusive report ! Access now – it’s free

The 3,400m2 facility will offer a modern, state-of-the-art work environment, featuring three media tanks and six buffer tanks to support production of buffer and media solutions, with dedicated areas to meet the strictest hygiene and safety standards.

The station will be connected to the in-house logistics system as well as to the piping systems for upstream and downstream processes within the existing infrastructure.

Additionally, automation capabilities and ergonomically designed workstations will facilitate faster and more efficient processes and support the firm’s sustainability goals.

A commitment to progress in biotech

Benedikt von Braunmühl, Chief Executive Officer of Rentschler Biopharma, commented: “At Rentschler Biopharma, we invest with foresight in infrastructure that ensures stability and sustainable growth – always keeping in mind our clients and, above all, patients worldwide.

“The new buffer media station marks an important milestone in this regard and, as the largest single investment in our history at our headquarters, underscores our clear commitment to Laupheim as well as to Germany and Europe as leading biotech hubs.”

The company held an event on 10 October to mark its construction progress, which included a panel discussion that highlighted how investments and innovation are shaping future viability and competitiveness in the biotech sector.

As the largest single investment in our history at our headquarters, [the new buffer media station] underscores our clear commitment to Laupheim as well as to Germany and Europe as leading biotech hubs”

Christiane Bardroff, Chief Operating Officer of Rentschler Biopharma, explained: “… enhanced automation and digitalisation will make our processes more efficient and secure, while providing employees with a state-of-the-art working environment.

“With additional capacity for buffer and media solutions, we are laying the foundation to respond flexibly to our clients’ growing needs while ensuring patients have reliable access to therapies.”

The new facility in Laupheim is expected to be operational by 2028.

Share via
Share via